和铂-B(02142.HK) 宣布与由生成式人工智能(Gen AI)驱动的临床阶段生物技术公司英硅智能达成战略合作，将利用各自在抗体发现与人工智能领域的技术优势，加速新型治疗性抗体的研发进程。
根据合作协议，双方将结合和铂医药行业领先的技术平台、专有数据集及在抗体开发领域的丰富经验，与英硅智能在构建一体化AI驱动药物研发平台方面的技术优势，共同推进AI赋能的抗体发现算法和应用开发。
双方并将合作开展针对新型特异性抗体的早期药物发现项目，旨在为免疫学、肿瘤学和神经科学领域尚未被满足的医疗需求提供创新的解决方案。(gc/da)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.